Target intelligence / Profile preview

Potassium voltage-gated channel subfamily C member 2 and member 4 (Kv3.2 and Kv3.4)

Target
Kv3.2 and Kv3.4
Molecular classification
Ion channel, Voltage-gated potassium channel, Shaw-related subfamily
01

Overview

Voltage-gated potassium channels Kv3.2 (KCNC2) and Kv3.4 (KCNC4) are members of the Shaw-related subfamily, distinguished by their high activation thresholds and ultra-fast gating kinetics. These unique biophysical properties allow them to mediate rapid repolarization of action potentials, which is essential for the high-frequency firing (fast-spiking) phenotype of specific neuronal populations, such as parvalbumin-positive GABAergic interneurons in the cortex and hippocampus. Kv3.2 is primarily localized in the central nervous system and plays a critical role in maintaining the balance between excitation and inhibition; its dysfunction is linked to schizophrenia, epilepsy, and hearing disorders. Kv3.4 is expressed in both the brain and peripheral sensory neurons, such as dorsal root ganglion (DRG) cells, where it regulates nociceptive signaling and has been implicated in the pathogenesis of Alzheimer's and Parkinson's diseases. Therapeutic development focuses on positive allosteric modulators (PAMs), such as the AUT series of compounds, which aim to restore neuronal firing patterns in neuropsychiatric conditions. Conversely, Kv3.4 inhibition is explored as a strategy for managing chronic pain and neurodegeneration.

Other names
KCNC2KCNC4Voltage-gated potassium channel Kv3.2Voltage-gated potassium channel Kv3.4Shaw-related subfamily member 2Shaw-related subfamily member 4Raw3hKCNC2hKCNC4
02

Mechanism of action

Positive allosteric modulation (PAM) of Kv3.1/3.2 channels; Voltage-gated channel blocking; Gating modification

03

Biological functions

Fast action potential repolarizationHigh-frequency neuronal firingNeurotransmitter release regulationAxon growth and guidanceSensory processingGamma oscillation synchronization
04

Disease associations

SchizophreniaEpilepsyAlzheimer's diseaseParkinson's diseaseChronic painHearing lossTinnitusFragile X syndromeBipolar disorder
05

Safety considerations

Seizure riskCognitive impairmentPotential cardiac rhythm disturbancesOff-target effects on other Kv subfamilies
06

Interacting drugs

AUT00206

6 more in the full profile.

07

Biomarkers

Gamma oscillations (EEG)Auditory mismatch negativity (MMN)Striatal activation (fMRI)KCNC2 genetic variants

Beyond the preview

Go deeper on Potassium voltage-gated channel subfamily C member 2 and member 4 (Kv3.2 and Kv3.4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Potassium voltage-gated channel subfamily C member 2 and member 4 (Kv3.2 and Kv3.4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call